Gastric/GEJ cancer: 3rd-line nivolumab boosts OS

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Nivolumab offers improved OS compared with placebo as a third-line therapy for patients with advanced gastric or gastroesophageal junction (GEJ) cancer who are refractory or intolerant to ≥2 lines of chemotherapy.

Why this matters

  • Current guidelines offer no guidance on third-line therapy for patients in whom prior chemotherapy regimens have failed to treat advanced gastric or gastroesophageal junction cancer.

Study design

  • Randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (ATTRACTION-2).
  • 493 patients with advanced or recurrent gastric or gastroesophageal junction cancer previously treated with ≥2 chemotherapy regimens received nivolumab (n=330) or placebo (n=163).
  • Funding: Ono Pharmaceutical and Bristol-Myers Squibb.

Key results

  • Significantly longer median OS in nivolumab group vs placebo (5.26 mo vs 4.14 mo).
  • 68.5% of nivolumab and 86.5% of placebo patients died (HR, 0.63; P<.0001>
  • Risk for disease progression lower in the nivolumab group vs placebo (HR, 0.60; 95% CI, 0.49-0.75), with median PFS 1.61 mo with nivolumab and 1.45 mo with placebo.
  • 10% of nivolumab group reported grade 3-4 adverse events (AEs) vs 4% in placebo; 5 patients in nivolumab and 2 in placebo group died from treatment-related AEs.

Limitations

  • No data on QoL.